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Reduced dietary sodium intake (sodium reduction) increases heart rate in some studies of
animals and humans. As heart rate is independently associated with the development of
heart failure and increased risk of premature death a potential increase in heart rate could
be a harmful side-effect of sodium reduction. The purpose of the present meta-analysis
was to investigate the effect of sodium reduction on heart rate. Relevant studies were
retrieved from an updated pool of 176 randomized controlled trials (RCTs) published in the
period 1973–2014. Sixty-three of the RCTs including 72 study populations reported data
on heart rate. In a meta-analysis of these data sodium reduction increased heart rate with
1.65 beats per minute [95% CI: 1.19, 2.11], p < 0.00001, corresponding to 2.4% of the
baseline heart rate. This effect was independent of baseline blood pressure. In conclusion
sodium reduction increases heart rate by as much (2.4%) as it decreases blood pressure
(2.5%). This side-effect, which may cause harmful health effects, contributes to the need
for a revision of the present dietary guidelines.
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INTRODUCTION
About 0.5 g salt per day is sufficient to maintain vital physiological effects, but a daily habitual salt
intake up to 40 g has been described (Battarbee, 1978). Sixty-five percent of theWorld’s populations
eat salt in the interval 8–10 g and 95% in the interval 6–12 g (McCarron et al., 2013). Consequently,
world-wide the salt intake is very tightly regulated (Geerling and Loewy, 2008) in the low end of the
tolerable interval of 0.5–40 g. Still, some health institutions consider this salt intake to be unhealthy
due to an assumed association of sodiumwith blood pressure (BP) (WHO, 2012; US Department of
Health and Human Services, 2015), and therefore recommend lowering sodium intake below 100
mmol (2300mg, 5.8 g salt) (Box 1). However, meta-analyses question this assumption, as the effect
of sodium reduction (SR) on BP is only 1.27/0.05 mmHg in individuals with a normal BP (Graudal
et al., 2011) without indication of a dose-response relationship (Graudal et al., 2015). A moderate
effect in individuals with hypertension (5.5/2.75mmHg) (Graudal et al., 2011) does not justify SR
for the whole population.
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BOX 1 |
1000mg of sodium (Na) corresponds to 2542 mg salt (NaCl) (43 mmol). 100
mmol NaCl corresponds to 2299 mg of sodium and 5844 mg of salt. In this
article we use the term “sodium” and the unit “mmol.”
Compensating physiological mechanisms, like increases in
renin and aldosterone (Brunner et al., 1972; Graudal et al.,
1998) and noradrenalin and adrenalin (Graudal et al., 1998,
2011) during reduced sodium intake may contribute not only
to maintain BP, but also to increase heart rate (HR). Animal
experiments have shown that sodium reduction to one tenth of
normal intake increase HR with 25% in rats (Ely et al., 1985).
Folkow et al. concluded that “when it comes to the potential
impact of the salt intake level which, when altered, in most
subjects change BP and HR in opposite directions, these two
parameters should be carefully and jointly analyzed” and “in
studies of the effects of salt intake on blood pressure, influences
on heart rate are usually neglected even though the long-term
load on both left ventricle and systemic arteries is better related
to the product of HR × BP than to pressure alone” (Folkow and
Ely, 1998). This indication of the clinical importance of HR is
further emphasized by prospective observational studies, which
have shown that HR is independently associated with mortality
(Jensen et al., 2012; Ho et al., 2014), just as BP (Lewington et al.,
2002). Such an effect on HR could contribute to the finding of
an association of low sodium intake with increased mortality in
several population studies (Graudal et al., 2014; O’Donnell et al.,
2014; Pfister et al., 2014).
The purpose of the present meta-analysis was to investigate
the effect of SR on HR at different blood pressure levels. We also
intended to identify longitudinal studies to define a time point for
maximal efficacy of SR on HR and studies investigating different
doses of sodium intake to establish a dose-response relationship
between sodium intake and HR.
METHODS
Trial Search
Studies to be included were selected from an updated pool of
trials identified in a previous review (Graudal et al., 2011), in
which the details of the search procedure are described. Using
this procedure the literature search was updated in April 2015.
Types of Studies
Only randomized controlled trials (RCTs) were included.
Participants
Studies of healthy persons or persons with hypertension
irrespective of age and race were included. Studies systematically
investigating patients with diseases other than elevated BP (e.g.,
diabetes or heart failure), were excluded.
Intervention
The intervention is reduced sodium chloride intake (sodium
reduction: SR). Studies, in which reduced sodium intake was
controlled by means of 24-h urine sodium excretion or 8-h urine
FIGURE 1 | Flow diagram of the trial identification.
sodium excretion, were included. Studies not designed to control
for the confounding effect of co-interventions were excluded, i.e.,
studies treating persons with a concomitant intervention such
as an antihypertensive medication, potassium supplementation
or weight reduction were only included if the concomitant
intervention was identical in both the reduced and the usual
sodium diet groups.
Primary Outcome
Effect on HR calculated as the difference between the change
during intervention in the low and usual sodium intake dietary
groups. HR is measured as beats per minute (bpm) on the first
and the last day of the intervention.
Supplementary Analysis
The effect of SR on HR in subgroups defined by the 25, 50,
and 75% BP-distribution percentiles of the American population
(Wright et al., 2011) were investigated.
Secondary Outcomes
The within study effect of SR on HR at different time points and
at different doses of sodium reduction.
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TABLE 1 | Study characteristics and references of included studies.
No. Study ID Dur. Days N Age (years) Sodium reduction mmol HR (beats/min) References
1 Paulsen 4 22 24 47 54.0 Scand J Clin Lab Invest 2009;69:323–9
2 Seals 90 35 63.5 46 68.0 J Am Coll Cardiol 2001;38:506–13
3 Morgan 14 16 63 50 77.0 J Hum Hypertens 1988;1:311–5
4 Grobee 42 40 24 72 70.0 BMJ 1987;293:27–9
5 Dickinson 42 25 35.1 42 68.0 Atherosclerosis 2014;232:211–6
6 Ishimitsu N 7 7 53 195 64.0 Clin Sci 1996;91:293–8
7 Fotherby 35 17 73 79 75.0 J Hypertens 1993;11:657–63
8 He B 42 69 50 44 68.0 Hypertension 2009;54:482–8
9 ANHMRCDSSMC 48 103 58.4 63 75.7 Lancet 1989;1:399–402
10 Doig 4 8 25 117 J Cardiovasc Pharm 1995;25:511–17
11 Sharma 6 23 25 246 64.3 J Hypertens 1991;9:329–35
12 Gillies 42 24 56.7 77 67.2 Clin Exp Pharm Phys 1984;11:395–8
13 Starmans-Kool 14 10 32 97 56.0 J Appl Physiol 2011;110:468–71
14 Jessani 7 184 49.5 81 82.0 Am J Hypertens 2008;21:1238–1244
15 Beeks 7 117 53.4 99 63.5 Hypertension 2004;44:419–23
16 Wing 42 17 61 59 80.0 Blood Pressure 1998;7:299–307
17 Schorr 28 16 64.1 61 78.0 J Hypertens 1996;14:131–5
18 Fliser 7 7 25.5 180 59.0 Eur J Clin Invest 1995;25:39–43
19 Bruun H 4 12 47 331 73.0 J Hypertens 1990;8:219–27
20 Chiolero H 7 38 43 183 76.0 J Hypertens 2000;36:631–7
21 Benetos 28 20 41.5 78 75.3 J Hypertens 1992;10:355–60
22 Skrabal 14 52 23 156 69.3 Hypertension 1984;6:152–8
23 Ferri 14 61 47.1 264 73.2 J Am Soc Nephrol 1996;7:443–53
24 Sharma 7 40 25 214 61.0 Hypertension 1990;16:407–13
25 Davrath 5 8 25.1 96 63.5 Aviat Space Env Med 1999;70:577–82
26 Miller 14 36 23.4 58 60.0 Psychosom Med 1995;57:381–9
27 Ishimitsu H 7 23 55 193 59.7 Clin Sci 1996;91:293–8
28 Cooper 24 113 16.3 64 81.0 J Hypertens 1984;2:361–6
29 Bonfils N 5 12 39 140 64.0 J Hypertens 2013;31:2220–9
30 Graffe 4 21 26 172 65.0 Am J Physiol Renal Physiol
2012;15:F264–75
31 Tzemos 5 16 27 149 67.0 Hypertension 2008;51:1525–35
32 Dishy 6 25 34 300 67.0 J Hypertens 2003;21:153–7
33 Zanchi 7 9 25 250 66.0 J Clin Endocrin Metab 2004;89:1140–5
34 Burnier 7 15 22.7 188 71.0 J Hypertens 2000;18:1657–64
35 Bech 5 12 23.8 235 56.0 Am J Physiol 1998;274:914–23
36 Herlitz 4 6 46 98 73.0 Blood Press 1998;7:47–52
37 He W 42 71 52 55 65.0 Hypertension 2009;54:482–8
38 Hyperpath C2 7 211 49.2 211 63.5 Hypertension 2012;60:1359–66
39 Draaijer 7 10 41 259 69.8 J Hum Hypertens 1995;9:263–9
40 Schorr 7 187 25 206 56.6 J Hypertens 1999;17:475–9
41 Ambrosioni 42 25 23 60 76.0 Hypertension 1982;4:789–94
42 He A 42 29 47 68 67.0 Hypertension 2009;54:482–8
43 Chiolero N 7 12 40 201 67.0 J Hypertens 2000;36:631–7
44 Sullivan N 4 27 28.8 146 61.0 Hypertension 1980;2:506–14
45 Fuchs 9 17 20 229 64.7 Brazi J Med Biol Res 1987;20:25–34
46 Sullivan H 4 19 27 153 64.0 Hypertension 1980;2:506–14
47 Johnson 14 40 68.8 73 J Hypertens 2001;19:1053–60
48 Cuzzola 14 19 47 161 71.0 Am J Hypertens 2001;14:224–30
49 Stein 5 7 33.7 183 61.2 Clin Pharm Ther 1995;58:425–33
50 Parker 28 59 52 73 74.0 Hypertension 1990;16:398–406
(Continued)
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TABLE 1 | Continued
No. Study ID Dur. Days N Age (years) Sodium reduction mmol HR (beats/min) References
51 Uzu 7 70 50.5 173 64.8 Am J Hypertens 1999;12:35–9
52 Mallamaci 14 32 48 165 70.0 J Hypertens 2013;31:1424–30
53 Bonfils OW 5 12 39 157 68.0 J Hypertens 2013;31:2220–9
54 Damgaard 7 12 56.8 129 64.0 Am J Physiol - Reg Integ Comp Physiol
2006;290:R1294-R1301
55 Bruun N 4 10 46 341 60.0 J Hypertens 1990;8:219–27
56 Mark 10 6 28 305 63.3 Circ Res 1975;(Suppl 1):36–7: I194–I198
57 Overlack 7 46 45.3 245 64.7 Am J Hypertens 1995;8:829–36
58 Ruppert 7 163 38 274 63.2 Hypertens 1993;11:743–9
59 Fliser 16 16 25 187 77.1 J Hypertens 1993;6:320–4
60 Sciarrone 56 91 53.5 82 J Hypertens 1992;10:287–98
61 Allen 5 70 24 83 72.0 J Hypertens 2014;32:374–82
62 Mak 7 13 24 190 56.0 Eur Heart Journal Cardiovascular Imaging
2013;14:1092–8
63 Inoue 7 14 46 293 71.5 J Hum Hypertens 1996;10:523–9
64 Townsend 6 20 30 171 67.0 Clin Sci (London) 2007;113:141–8
65 Boero 14 13 51 209 76.0 Min Urol Nefrol 2000;52:13–6
66 Hargreaves 14 8 23.4 106 59.0 Clin Sci 1989;76:553–7
67 Skrabal 14 20 23 150 62.2 Lancet 1981; II:895–900
68 Carey C1 7 185 47 203 68.1 Hypertension 2012;60:1359–66
69 Bonfils H 5 12 43 131 73.0 J Hypertens 2013;31:2220–9
70 Sudhir 12 6 34.7 133 61.0 Clin Sci 1989;77:605–10
71 Melander 28 39 53 89 67.7 J Hypertens 2007;25:619–27
72 Friberg 13 10 33.3 117 63.0 Hypertension 1990;16:121–30
Data Extraction
Two authors independently recorded the following data from
each trial: HR (SD) before and after intervention for each
measurement time and for each dose of sodium reduction; the
sample size (N); the mean age of participants; SR measured as the
difference between 24-h urinary sodium excretion during low-
sodium and usual-sodium diets and standard deviation (SD); SBP
(SD) and DBP (SD) before and after intervention. If there were
discrepancies between reviewers they looked at the data together
and came to an agreement.
Risk of Bias (Quality) Assessment
This was performed using the Cochrane Risk of bias tool,
including recording of allocation, blinding, incomplete outcome
data, and selective reporting (Higgins and Green, 2011).
Reporting bias was evaluated by an estimate of asymmetry in
Funnel plots (Cochrane Collaboration, 2011; Higgins and Green,
2011).
Heterogeneity
A chi-squared test included in the forest plot was used to
assess whether observed differences in results are compatible
with chance alone. A low P value (or a large chi-squared
statistic relative to its degree of freedom) provides evidence of
heterogeneity of intervention effects (variation in effect estimates
beyond chance) (Higgins and Green, 2011).
TABLE 2 | Mean heart rate effect of sodium reduction stratified by blood
pressure quartiles of the American population.
Systolic BP
percentile, mmHg
Number of
studies
(participants)
Heart rate, MD
(95%CI)
(beats/min)
Z (p)
0–25 %, −110 3 (304) 0.91 [0.37, 1.45] 3.28 (0.001)
25–50 %, 110–119 18 (1204) 2.18 [1.26, 3.11] 4.62 (0.00001)
50–75 %, 119–131 20 (1472) 1.99 [0.72, 3.27] 3.06 (0.002)
75–100 %, 131 – 31 (2452) 1.41 [0.75, 2.07] 4.21 (0.0001)
Data Synthesis
The HR outcome was defined as the weighted mean difference
(MD) between the changes from baseline to end of treatment
during low and usual sodium diets. The combined effect
measures were compared by means of the inverse variance
method in Review Manager (Cochrane Collaboration, 2011). As
we accumulated data from a series of studies that had been
performed by researchers operating independently, and as the
goal of the analysis was to extrapolate to other populations, we
used a random effect model in our primary analysis to estimate
the summary measure as the mean of a distribution of effects. In
a secondary analysis we used a fixed-effect model assuming that
the true effect size for all studies is identical. As we move from
random effect to fixed effect, extreme studies will gain influence
if they are large, and will lose influence if they are small. If there
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is no heterogeneity (tau2 = 0 and I2 = 0), the two models are
identical.
RESULTS
Trial Identification
The last update of the 2011 search was performed April 15 2015.
During the update the de-duplicated results from the searches
revealed 728 articles. On the basis of headlines 645 were excluded.
Eighty-three abstracts were read and 33 full articles obtained of
which 12 fulfilled the inclusion criteria. During the process we
identified 3 duplicates in the 2011 review (Graudal et al., 2011),
which were eliminated. A total of 176 references (164 from the
2011 review plus 12 new references) were thus included in the
present updated version. These 176 references included 198 study
populations. Information onHRwas available in 72 of these study
populations, described in 63 references. Figure 1 shows a flow
diagram of the trial identification.
Trial Characteristics
The 72 study populations included in the present meta-analysis
are shown in Table 1.
Effect of SR on HR
Figure 2 shows that the effect of SR is highly significant, although
clinically small: 1.65 bpm [95%CI: 1.19, 2.11], p < 0.00001,
random effect, or 1.40 bpm [95% CI: 1.05, 1.75], fixed effect. As
the mean baseline HR for the whole population was 67.8 bpm,
this corresponds to an effect of 2.4% (1.65/67.8). Table 2 shows
the effect of SR on HR in BP-distribution quartiles defined by
quartiles of the American population (Wright et al., 2011). The
effect of SR on HR was significant in all four quartiles indicating
that the effect of SR on HR is independent of the baseline BP.
The most contrasting risk of bias element was blinding (24
double-blind vs. 48 open studies). In 24 double-blind studies
(n = 1386) the effect of SR was 1.34 bpm [0.54, 2.15], p <
0.001, random and fixed effect (I2 = 0%). In 48 open studies
(n = 4040) the effect of SR was 1.83 bpm [1.24, 2.43], p <
0.00001, random effect, or 1.42 bpm [1.03, 1.81], p < 0.00001,
fixed effect (I2 = 18%).
Longitudinal Effect of SR on HR
Only 2 studies gave such results. In the study by Ruppert et al.
(1993) the effect of SR on HR was 1.6 bpm at week 1 and 1.1 bpm
at week 4. In the study by Fuchs et al. (1987) the outcome varied
at 3, 6, and 9 days but without an obvious trend (Table 3).
Dose-Response Relationship of SR vs. HR
Table 3 shows the outcome of seven dose-response analyses in
four RCTs (Fuchs et al., 1987; Bruun et al., 1990; Burnier et al.,
2000; Johnson et al., 2001). The trend is that HR increases with
increasing SR but the number of investigations is few and the
differences are small.
DISCUSSION
This meta-analysis shows that SR increases HR. The increase
is statistically highly significant (Z = 7.0, p < 0.00001), but
the clinical significance of the size of the increase, which is
1.65 bpm corresponding to 2.4%, is debatable. The effect size
matches quantitatively the effect of SR on SBP in the investigated
RCTs, which is 3.4 mmHg (mean baseline SBP = 135 mmHg),
corresponding to 2.5% (3.4/135). However, in contrast to the
BP effect, which is moderate in hypertensives and low in
normotensives, the HR effect is independent of baseline BP. This
means that individuals with a BP in the lower 50% percentile
of the BP distribution may get an increase in HR without a
reduction in BP. Study blinding had no significant influence
on the effect size. Two longitudinal studies were too few to
determine the time of maximal efficacy (Fuchs et al., 1987;
Ruppert et al., 1993). Seven dose-response relationships from 4
RCTs (Fuchs et al., 1987; Bruun et al., 1990; Burnier et al., 2000;
Johnson et al., 2001) indicate that a dose-response relationship
does exist, but the data are not sufficient for a reliable conclusion.
Previously we have shown that ethnicity only has a minor impact
on BP (Graudal and Jürgens, 2015), but we could not determine
whether ethnicity has an impact on the effect of SR on HR, as
only 2 Black and 4 Asian study populations were identified in the
present meta-analysis.
A series of population studies have not been able to
demonstrate a beneficial association between low sodium intake
and health outcomes. A recent IOM report [Institute of Medicine
(IOM), 2013] concluded “Science was insufficient and inadequate
to establish whether reducing sodium intake below 2300 mg/d
(100 mmol) either decreases or increases CVD risk in the general
population.” A later meta-analysis of these population studies
found that a sodium intake below 115 mmol was associated with
increased mortality, as was a sodium intake above 215 mmol
(Graudal et al., 2014). This U-shaped relation between sodium
intake and mortality has been identified in several individual
population studies (Thomas et al., 2011; O’Donnell et al., 2014;
Pfister et al., 2014). The reason for this U-shape could be that
SR has side effects as indicated in our previous meta-analysis,
which shows that SR significantly increases plasma renin, plasma
aldosterone, plasma adrenaline, plasma noradrenaline, plasma
cholesterol, and plasma triglyceride (Graudal et al., 2011). In
addition, the present finding of an increase in HR can be
considered a side-effect, because HR has been associated with
mortality (Jensen et al., 2012; Ho et al., 2014) and development of
heart insufficiency (Pfister et al., 2012) in observational studies.
In the Copenhagen City Study a 10 bpm increase in resting
HR was associated with increased cardiovascular and all-cause
mortality in both univariate (about 20%) and multivariate (about
10%) models (Jensen et al., 2012), and in the Framingham study
an 11 bpm increase in resting HR was also associated with
increased cardiovascular (18%) and all-cause (17%) mortality
(Ho et al., 2014). A 20mmHg increase in SBP leads to about 100%
increase in mortality (Lewington et al., 2002). Assuming that
these associations are linear, it can be estimated that an increase
in HR of about 3 bpm outbalances the effect of a reduction
in SBP of 1 mmHg. As mentioned the clinical significance of
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FIGURE 2 | Forrest plot showing effect of sodium reduction on heart rate in 72 study populations. The overall effect of sodium reduction is 1.65 b.p.m. The
studies are ordered according to the effect size and correspond to the order in Table 1.
TABLE 3 | Changes in mean heart rate in studies investigating different doses of sodium.
References Minor sodium reduction (b/m) Moderate sodium reduction Extreme sodium reduction Study Duration, days
45 Fuchs (1987) NA 4.6 3.3 3
45 Fuchs (1987) NA 1.5 1.5 6
45 Fuchs (1987) NA −0.9 4.5 9
19 Bruun (1990) (N) NA 1 2 4
19 Bruun (1990) (H) NA 0 1 4
34 Burnier (2000) NA 1 2 7
47 Johnson (2001) −1 1.2 1.8 14
a 2.4% increase in HR may be questionable. However, the SR
recommendations of the health institutions are based on the
assumption that a small BP reduction in the whole population
will lead to a significant reduction in mortality (WHO, 2012; US
Department of Health and Human Services, 2015). Assuming
that this concept is correct a 2.4% increase in HR should have
the opposite effect especially when combined with increases in
other factors know to be predictive of mortality, such as renin,
noradrenalin and cholesterol. Indeed, observational population
studies indicate that side effects of SR trump the BP effect
(Thomas et al., 2011; Graudal et al., 2014; O’Donnell et al.,
2014; Pfister et al., 2014). This seems to be the case, not only
in healthy normotensive individuals, but also in heart failure
patients. In a recent study of symptomatic patients with chronic
heart failure sodium restriction was associated with significantly
higher risk of death or HF-hospitalization (hazard rate = 1.85;
95% confidence interval: 1.21 to 2.84; p < 0.004) (Doukky
et al., 2016). These findings indicate that health institutions
in their Dietary Guidelines (US Department of Health and
Human Services, 2015; DeSalvo et al., 2016) to a greater extent
should recognize the lack of RCTs on the effect of SR on health
outcomes, the possible side effects of SR and the association
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of low sodium intake with increased mortality in observational
studies (Graudal, 2016). In the light of the ongoing debate, the
process of preparing guidelines should include “full transparency,
a lack of bias, and the inclusion and consideration of all of
the latest available research and scientific evidence, even that
which challenges current dietary recommendations” (Whoriskey,
2016). The present sodium recommendations do not fulfill
these criteria. In conclusion SR increases HR. This should be
considered a side-effect, which may have a harmful effect on
the general population. This effect contributes to the need for a
revision of the present dietary guidelines, which now has been
initiated by the American Congress (Whoriskey, 2016).
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